Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
neuroscience
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Volume 28, No. 1, Year 2004
Notification
URL copied to clipboard!
Description
Clozapine has been the gold standard for treatment of patients with refractory schizophrenia but is associated with serious safety liabilities. This has prompted the search for therapeutic alternatives for treatment-resistant schizophrenia. The objective of this study was to compare the efficacy and safety of olanzapine versus clozapine in schizophrenic patients who failed to respond adequately to antipsychotic medication or who experienced intolerable adverse effects associated with the medication. This 18-week, randomized, double-blind, parallel study compared treatment with either olanzapine (5-25 mg/day, n=75) or clozapine (100-500 mg/day, n=72) in patients with schizophrenia who were nonresponsive to, or intolerant of, standard acceptable antipsychotic therapy. At the 18-week endpoint, no statistically significant differences were found between olanzapine and clozapine in any efficacy measure used: Positive and Negative Syndrome Scale (PANSS) total, positive, negative, or general psychopathology or Clinical Global Impression severity (CGI-S). Response rates based on the criteria of Kane et al. [Arch. Gen. Psychiatry 45 (1988) 789] were also not significantly different between olanzapine-treated (57.9%) and clozapine-treated patients (60.8%). There were no significant differences in measurements of extrapyramidal symptoms or electrocardiography, and no clinically and statistically significant changes were seen in vital signs or laboratory measures in either group. Both treatments were well tolerated. Olanzapine demonstrated similar efficacy to clozapine in patients who had failed previous treatment because of lack of efficacy (treatment resistance) or intolerable side effects (treatment intolerance). Olanzapine therefore presents a safe alternative in the treatment of refractory schizophrenia. © 2003 Elsevier Inc. All rights reserved.
Authors & Co-Authors
Bitter, István
Hungary, Budapest
Semmelweis Egyetem
Austria, Vienna
Lilly Area Medical Center
Dossenbach, Martin
Austria, Vienna
Lilly Area Medical Center
Brook, Shlomo
South Africa, Krugersdorp
Sterkfontein Hospital
Feldman, Peter D.
United States, Indianapolis
Eli Lilly and Company
Metcalfe, Stephen
Austria, Vienna
Lilly Area Medical Center
Gagiano, Carllo A.
South Africa, Bloemfontein
University of the Free State
Füredi, János
Hungary, Budapest
National Institute of Psychiatry and Neurology
Bartko, György
Hungary, Budapest
Jahn Ferenc Dél-pesti Kórház, Budapest
Janka, Zoltan
Hungary, Szeged
Szegedi Tudományegyetem Általános Orvostudományi Kar
Banki, Csaba M.
Hungary
Regional Neuropsychiatric Institute
Kovács, Gábor G.
Hungary, Budapest
Central Military Hospital, Budapest
Breier, Alan
United States, Indianapolis
Eli Lilly and Company
Statistics
Citations: 123
Authors: 12
Affiliations: 10
Identifiers
Doi:
10.1016/j.pnpbp.2003.09.033
ISSN:
02785846
Research Areas
Disability
Mental Health